Literature DB >> 3554839

Clinical manifestations of Lyme disease.

A C Steere, N H Bartenhagen, J E Craft, G J Hutchinson, J H Newman, A R Pachner, D W Rahn, L H Sigal, E Taylor, S E Malawista.   

Abstract

Lyme disease typically begins with a unique skin lesion, erythema chronicum migrans (ECM) (stage 1). Patients with this lesion may also have headache, meningeal irritation, mild encephalopathy, multiple annular secondary lesions, malar or urticarial rash, generalized lymphadenopathy and splenomegaly, migratory musculoskeletal pain, hepatitis, sore throat, non-productive cough, conjunctivitis, periorbital edema, or testicular swelling. After a few weeks to months (stage 2), about 15% of patients develop frank neurologic abnormalities, including meningitis, encephalitis, cranial neuritis (including bilateral facial palsy), motor or sensory radiculoneuritis, mononeuritis multiplex, or myelitis. At this time, about 8% of patients develop cardiac involvement--AV block, acute myopericarditis, cardiomegaly, or pancarditis. Throughout this stage, many patients continue to experience migratory musculoskeletal pain in joints, tendons, bursae, muscle, or bone. Months to years after disease onset (stage 3), about 60% of patients develop frank arthritis, which may be intermittent or chronic. Recently evidence suggests that Lyme disease may also be associated with chronic neurologic or skin involvement. Thus, Lyme disease occurs in stages with different clinical manifestations at each stage, but the course of the illness in each patient is highly variable.

Entities:  

Mesh:

Year:  1986        PMID: 3554839     DOI: 10.1016/s0176-6724(86)80123-7

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Mikrobiol Hyg A        ISSN: 0176-6724


  18 in total

1.  Epidemiological study of a cohort of adult patients with Erythema migrans registered in Slovenia in 1993.

Authors:  F Strle; V Maraspin; S Furlan-Lotric; J Cimperman
Journal:  Eur J Epidemiol       Date:  1996-10       Impact factor: 8.082

2.  Lyme carditis in immunodeficient mice during experimental infection of Borrelia burgdorferi.

Authors:  G Zimmer; U E Schaible; M D Kramer; G Mall; C Museteanu; M M Simon
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

3.  Coinfection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis alters murine immune responses, pathogen burden, and severity of Lyme arthritis.

Authors:  V Thomas; J Anguita; S W Barthold; E Fikrig
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Induction of indoleamine 2,3-dioxygenase by Borrelia burgdorferi in human immune cells correlates with pathogenic potential.

Authors:  Andrea C Love; Ira Schwartz; Mary M Petzke
Journal:  J Leukoc Biol       Date:  2014-11-24       Impact factor: 4.962

Review 5.  Population genetics, taxonomy, phylogeny and evolution of Borrelia burgdorferi sensu lato.

Authors:  Gabriele Margos; Stephanie A Vollmer; Nicholas H Ogden; Durland Fish
Journal:  Infect Genet Evol       Date:  2011-08-05       Impact factor: 3.342

6.  Unusual features in the epidemiology of Lyme borreliosis.

Authors:  L Angelov
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

7.  Persistent atrioventricular block in Lyme borreliosis.

Authors:  W Mayer; F X Kleber; B Wilske; V Preac-Mursic; W Maciejewski; H Sigl; E Holzer; W Doering
Journal:  Klin Wochenschr       Date:  1990-04-17

8.  Meningitis due to Borrelia burgdorferi in the initial stage of Lyme disease.

Authors:  H I Huppertz; V Sticht-Groh
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

9.  Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.

Authors:  F Strle; V Preac-Mursic; J Cimperman; E Ruzic; V Maraspin; M Jereb
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

10.  Infections following tickbites. Tick-borne encephalitis and Lyme borreliosis--a prospective epidemiological study from Tyrol.

Authors:  E Schmutzhard; G Stanek; M Pletschette; A M Hirschl; A Pallua; R Schmitzberger; R Schlögl
Journal:  Infection       Date:  1988 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.